Cooper Companies’ (COO) “Buy” Rating Reiterated at Raymond James Financial

Raymond James Financial reissued their buy rating on shares of Cooper Companies (NYSE:COO) in a research note released on Monday. Raymond James Financial currently has a $265.00 price target on the medical device company’s stock.

A number of other brokerages have also recently issued reports on COO. Robert W. Baird restated a buy rating and issued a $273.00 target price (up from $267.00) on shares of Cooper Companies in a report on Tuesday, September 12th. Zacks Investment Research upgraded Cooper Companies from a hold rating to a buy rating and set a $277.00 target price on the stock in a report on Tuesday, August 29th. Jefferies Group set a $250.00 target price on Cooper Companies and gave the stock a buy rating in a report on Thursday, August 17th. Oppenheimer restated a hold rating and issued a $250.00 target price on shares of Cooper Companies in a report on Tuesday, September 12th. Finally, Cleveland Research restated a buy rating on shares of Cooper Companies in a report on Tuesday, August 22nd. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Cooper Companies presently has a consensus rating of Buy and a consensus price target of $260.70.

Cooper Companies (NYSE COO) opened at $238.80 on Monday. The company has a quick ratio of 1.29, a current ratio of 2.51 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $11,350.84, a price-to-earnings ratio of 24.80, a P/E/G ratio of 1.94 and a beta of 0.54. Cooper Companies has a 1-year low of $165.98 and a 1-year high of $256.39.

Cooper Companies (NYSE:COO) last issued its earnings results on Wednesday, December 6th. The medical device company reported $2.65 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.66 by ($0.01). The company had revenue of $561.50 million during the quarter, compared to analyst estimates of $558.86 million. Cooper Companies had a return on equity of 16.00% and a net margin of 16.45%. The business’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.28 earnings per share. analysts anticipate that Cooper Companies will post 9.72 earnings per share for the current fiscal year.

In other news, Director Gary S. Petersmeyer sold 3,977 shares of Cooper Companies stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $244.94, for a total transaction of $974,126.38. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COO. Janus Henderson Group PLC boosted its position in Cooper Companies by 558.5% during the second quarter. Janus Henderson Group PLC now owns 2,175,791 shares of the medical device company’s stock valued at $520,937,000 after purchasing an additional 1,845,368 shares during the last quarter. Pioneer Investment Management Inc. boosted its position in Cooper Companies by 136.6% during the second quarter. Pioneer Investment Management Inc. now owns 1,226,250 shares of the medical device company’s stock valued at $293,589,000 after purchasing an additional 708,028 shares during the last quarter. Koch Industries Inc. acquired a new stake in Cooper Companies during the second quarter valued at $312,000. Voya Investment Management LLC boosted its position in Cooper Companies by 973.4% during the second quarter. Voya Investment Management LLC now owns 329,015 shares of the medical device company’s stock valued at $78,773,000 after purchasing an additional 298,363 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Cooper Companies during the second quarter valued at $71,050,000. 96.79% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Cooper Companies’ (COO) “Buy” Rating Reiterated at Raymond James Financial” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/12/08/cooper-companies-coo-buy-rating-reiterated-at-raymond-james-financial.html.

Cooper Companies Company Profile

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply